Skip to main content

Advertisement

SpringerLink
Log in

EMMPRIN and ADAM12 in prostate cancer: preliminary results of a prospective study

  • Research Article
  • Published:
Tumor Biology

Abstract

Extracellular metalloproteinase inducer (EMMPRIN) and a disintegrin and metalloproteinase (ADAM12) play a major role in cancer invasion and metastasis owing to the fact that they are directly related to the cell microenvironment and extracellular matrix (ECM) degradation. The aim of this study was to search for an answer to the question “whether the determination of EMMPRIN and ADAM12 values especially in urine may be helpful for the early diagnosis of prostate cancer without employing invasive methods” and also to check whether they may be useful for the determination of the patients with high metastasis risk. Peripheral blood and urine from 66 prostate cancer patients (40 local, 20 locally advanced, 6 metastatic) and 14 healthy controls were evaluated by enzyme-linked immunosorbent assay (ELISA) method. Serum EMMPRIN and ADAM12 values of the patients were seen to be statistically higher than the serum EMMPRIN and ADAM12 values of the healthy controls (p = 0.01 and p = 0.001, respectively). The urine ADAM12 levels were significantly higher in patients (p = 0.013). No significant relationships were found between urine EMMPRIN values of the patients and the healthy controls (p > 0.05). Positive correlation between urine EMMPRIN–urine ADAM12 tests was found in total patients group (r = 0.683, p = 0.001). Our preliminary results revealed that serum EMMPRIN and ADAM12 values and urine ADAM12 values may be useful markers in prostate cancer therapy. Due to the high correlation between these two tests, we are of the opinion that the use of urine ADAM12 in clinic may be sufficient and favorable together with prostate-specific antigen (PSA) for treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Van Hoorde L, Van Aken E, Mareel M. Collagen type I: a substrate and a signal for invasion. Prog Mol Subcell Biol. 2000;25:105–34.

    Article  PubMed  Google Scholar 

  2. Aksun SA, Özmen D, Bayındır O. Metalloproteinazlar, inhibitörleri ve ilişkili fizyolojik ve patolojik durumlar. Turk Klin J Med Sci. 2001;21:332–42.

    Google Scholar 

  3. Reel B. Matriks metalloproteinaz enzimleri ve ateroskleroz. Turk Klin J Med Sci. 2006;26:527–37.

    CAS  Google Scholar 

  4. van Hinsbergh VWM, Engelse MA, Quax PH. Pericellular proteases in angiogenesis and vasculogenesis. Arterioscler Thromb Vasc Biol. 2006;26:716–28.

    Article  PubMed  Google Scholar 

  5. Roy R, Yang J, Moses MA. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol. 2009;27:5287–97.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  6. Riethdorf S, Reimers N, Assmann V, Kornfeld JW, Terracciano L, Sauter G, et al. High incidence of EMMPRIN in human tumors. Int J Cancer. 2006;119:1800–10.

    Article  CAS  PubMed  Google Scholar 

  7. Biswas C. Tumor cell stimulation of collagenase production by fibroblasts. Biochem Biophys Res Commun. 1982;109:1026–34.

    Article  CAS  PubMed  Google Scholar 

  8. Biswas C, Zhang Y, DeCastro R, Guo H, Nakamura T, Kataoka H, et al. The human tumor cell-derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily. Cancer Res. 1995;55:434–9.

    CAS  PubMed  Google Scholar 

  9. Tang Y, Nakada MT, Kesavan P, McCabe F, Millar H, Rafferty P, et al. Extracellular matrix metalloproteinase ınducer stimulates tumor angiogenesis by elevating vascular endothelial growth factor and matrix metalloproteinases. Cancer Res. 2005;65:3193–9.

    CAS  PubMed  Google Scholar 

  10. Bougatef F, Quemener C, Kellouche S, Naïmi B, Podgorniak MP, Millot G, et al. EMMPRIN promotes angiogenesis through hypoxia-inducible factor-2alpha-mediated regulation of soluble VEGF isoforms and their receptor VEGFR-2. Blood. 2009;114:5547–56.

    Article  CAS  PubMed  Google Scholar 

  11. Huovila AP, Turner AJ, Pelto-Huikko M, Karkkainen I, Ortiz RM. Shedding light on ADAM metalloproteinases. Trends Biochem Sci. 2005;30:413–22.

    Article  CAS  PubMed  Google Scholar 

  12. Wolfsberg TG, White JM. ADAM metalloproteases. In: Barrett AJ, Rawlings ND, Woessner JF, editors. Handbook of proteolytic enzymes. London: Academic; 2003. p. 1310–3.

    Google Scholar 

  13. Reiss K, Saftig P. The “A Disintegrin And Metalloprotease” (ADAM) family of sheddases: physiological and cellular functions. Semin Cell Dev Biol. 2009;20:126–37.

    Article  CAS  PubMed  Google Scholar 

  14. Kumar RJ, Barqawi AB, Crawford ED. Epidemiology of prostate cancer. US Oncol Rev. 2005;1:1–6.

    CAS  Google Scholar 

  15. Tosoian J, Loeb S. PSA and beyond: the past, present, and future of investigative biomarkers for prostate cancer. Sci World J. 2010;10:1919–31.

    Article  CAS  Google Scholar 

  16. Verrier S, Hogan A, McKie N, Horton M. ADAM gene expression and regulation during human osteoclast formation. Bone. 2004;35:34–46.

    Article  CAS  PubMed  Google Scholar 

  17. Georges S, Chesneau J, Hervouet S, Taurelle J, Gouin F, Redini F, et al. A disintegrin and metalloproteinase 12 produced by tumour cells accelerates osteosarcoma tumour progression and associated osteolysis. Eur J Cancer. 2013;49:2253–63.

    Article  CAS  PubMed  Google Scholar 

  18. Roy R, Wewer UM, Zurakowski D, Pories SE, Moses MA. ADAM 12 cleaves extracellular matrix proteins and correlates with cancer status and stage. J Biol Chem. 2004;279:51323–30.

    Article  CAS  PubMed  Google Scholar 

  19. Roy R, Rodig S, Bielenberg D, Zurakowski D, Moses MA. ADAM12 transmambrane and secreted isoforms promote breast tumor growth: a distinct role for ADAM12-S protein in tumor metastasis. J Biol Chem. 2011;286:20758–68.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  20. Pories SE, Zurakowski D, Roy R, Lamb CC, Raza S, Exarhopoulos A, et al. Urinary metalloproteinases: noninvasive biomarkers for breast cancer risk assessment. Cancer Epidemiol Biomarkers Prev. 2008;17:1034–42.

    Article  CAS  PubMed  Google Scholar 

  21. Sanli O, Acar O, Celtik M, Oktar T, Kilicaraslan I, Ozcan F, et al. Should prostate cancer status be determined in patients undergoing radical cystoprostatectomy? Urol Int. 2006;77:307–10.

    Article  PubMed  Google Scholar 

  22. Fröhlich C, Albrechtsen R, Dyrskjøt L, Rudkjaer L, Ørntoft TF, Wewer UM. Molecular profiling of ADAM12 in human bladder cancer. Clin Cancer Res. 2006;12:7359–68.

    Article  PubMed  Google Scholar 

  23. Peduto L, Reuter VE, Sehara-Fujisawa A, Shaffer DR, Scher HI, Blobel CP. ADAM12 is highly expressed in carcinoma-associated stroma and is required for mouse prostate tumor progression. Oncogene. 2006;25:5462–6.

    Article  CAS  PubMed  Google Scholar 

  24. Han ZD, He HC, Bi XC, Qin WJ, Dai QS, Zou J, et al. Expression and clinical significance of CD147 in genitourinary carcinomas. J Surg Res. 2010;160:260–7.

    Article  CAS  PubMed  Google Scholar 

  25. Bi XC, Liu JM, Zheng XG, Xian ZY, Feng ZW, Lou YX, et al. Over-expression of extracellular matrix metalloproteinase inducer in prostate cancer is associated with high risk of prostate-specific antigen relapse after radical prostatectomy. Clin Invest Med. 2011;34:358.

    Google Scholar 

  26. Zhong WD, Liang YX, Lin SX, Li L, He HC, Bi XC, et al. Expression of CD147 is associated with prostate cancer progression. Int J Cancer. 2012;130:300–8.

    Article  CAS  PubMed  Google Scholar 

  27. Zhu H, Zhao J, Zhu B, Collazo J, Gal J, Shi P, et al. EMMPRIN regulates cytoskeleton reorganization and cell adhesion in prostate cancer. Prostate. 2012;72:72–81.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  28. Han ZD, Bi XC, Qin WJ, He HC, Dai QS, Zou J, et al. CD147 expression indicates unfavourable prognosis in prostate cancer. Pathol Oncol Res. 2009;15:369–74.

    Article  CAS  PubMed  Google Scholar 

  29. Zhong WD, Han ZD, He HC, Bi XC, Dai QS, Zhu G, et al. CD147, MMP-1, MMP-2 and MMP-9 protein expression as significant prognostic factors in human prostate cancer. Oncology. 2008;75:230–6.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The present work was supported by the Research Fund of Istanbul University, Project No. 18287.

Conflicts of interest

None

Author information

Authors and Affiliations

  1. Basic Oncology Department, Institute of Oncology, University of Istanbul, 34093, Istanbul, Turkey

    Elif Bilgin Doğru, Ece Akşit & Vildan Yasasever

  2. Clinical Oncology Department, Institute of Oncology, University of Istanbul, Istanbul, Turkey

    Yavuz Dizdar

  3. Department of Urology, Faculty of Medicine, University of Istanbul, Istanbul, Turkey

    Feyyaz Ural & Öner Şanlı

Authors
  1. Elif Bilgin Doğru
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yavuz Dizdar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ece Akşit
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Feyyaz Ural
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Öner Şanlı
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Vildan Yasasever
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Elif Bilgin Doğru.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bilgin Doğru, E., Dizdar, Y., Akşit, E. et al. EMMPRIN and ADAM12 in prostate cancer: preliminary results of a prospective study. Tumor Biol. 35, 11647–11653 (2014). https://doi.org/10.1007/s13277-014-2514-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-014-2514-8

Keywords

Search

Navigation